SIMPONI Approved by European Commission as Ulcerative Colitis Treatment
Janssen Biologics' SIMPONI drug for treating active ulcerative colitis in adult patients has been approved by the European Commission.
SIMPONI is designed to treat moderately to severely active UC in patients who have not responded well to past conventional therapies. It is the first and only subcutaneous anti-tumor necrosis factor alpha treatment administered every four weeks for UC therapy.
More Articles on Gastroenterology:
GlaxoSmithKline Returns Drug Rights to ChemoCentryx After Failed Trial
5 Recent GI Center Openings, Plans & Expansions
"S" or "C" Corporation for Your Gastroenterology Practice: Maximize Tax Deductions by Using Both!
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.